<p>To look at in vivo eefct of empagliflozin in preventing diabetic nephropathy in the presence of high blood glucose. This study is aimed at looking at renoprotection of SGLT2 inhibition independent of its hypoglycaemic effect.</p
Background and Objective: Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transpo...
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabet...
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there h...
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patient...
Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,...
Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 ...
Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new and promising class of antidiabetic...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Chronic kidney disease is a frequent comorbidity in patients with diabetes mellitus (DM) and it incr...
Sodium Glucose Co-transporter2 inhibitors are one of the latest anti diabetic drugs that are approve...
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and...
Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the ...
<div><p>Background and Objective</p><p>Sodium glucose cotransporter 2 (SGLT2) is the main luminal gl...
Background and Objective: Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transpo...
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabet...
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there h...
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patient...
Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,...
Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 ...
Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new and promising class of antidiabetic...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
Chronic kidney disease is a frequent comorbidity in patients with diabetes mellitus (DM) and it incr...
Sodium Glucose Co-transporter2 inhibitors are one of the latest anti diabetic drugs that are approve...
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and...
Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the ...
<div><p>Background and Objective</p><p>Sodium glucose cotransporter 2 (SGLT2) is the main luminal gl...
Background and Objective: Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transpo...
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabet...
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there h...
DOI
Add to ORKG